Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Recruiting

Phase 2

Acolbifene vs. TamoxifenAcolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05941520

Conditions

Breast Atypical Hyperplasia

Breast Carcinoma

Breast Ductal Carcinoma In Situ

Breast Lobular Carcinoma In Situ

Eligibility Criteria

Sex: Female

Age: 35+

Healthy Volunteers: Not accepted

Interventions

Acolbifene Hydrochloride

Biospecimen Collection

Mammography

Questionnaire Administration

Random Periareolar Fine-Needle Aspiration

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-04-06.